Trial Profile

A Phase 1/2, Multi-Center, Open-Label Clinical Study Evaluating MDX2004 In Participants With Advanced Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 25 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MDX 2004 (Primary)
Indications Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors ModeX Therapeutics Inc

Most Recent Events

29 Oct 2025 According to OPKO Health media release, clinical dose selection analyses to support MDX2004 development will be showcased in a poster presentations at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), being held November 5-9, 2025.
28 Oct 2025 According to a ModeX Therapeutics Inc media release, first patient was dosed in this study.
04 Sep 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com